

ONLINE SUPPLEMENT

List of sites and investigators.


Site	Investigator
University of Cincinnati, Cincinnati, Ohio, USA	Mario Zuccarello, M.D., Todd Abruzzo, M.D., Lynn Money
Columbia University, New York, New York, USA	Jan Claassen, M.D., Cristina Falo, Ph.D.
University of Maryland, Baltimore, Maryland, USA	Francois Aldrich, M.D., Charlene Aldrich
Cleveland Clinic, Cleveland, Ohio, USA	Jennifer Frontera, M.D., Peter Rasmussen, M.D., Edward Manno, M.D., Javier Provencio, M.D., Joao Gomes, M.D., Moneen McBride, Erin Bynum
University of New Mexico, Albuquerque, New Mexico, USA	Andrew Carlson, M.D., Howard Yonas, M.D., Brittany Burlbaw, Theresa Wussow
Duke University, Durham, North Carolina, USA	Carmen Graffagnino, M.D., Kristina Riemen
Medical University of South Carolina, Charleston, South Carolina, USA	Raymond Turner, M.D., Adrian Parker, Emily Young
University of California, Los Angeles, California, USA	Paul Vespa, M.D., Courtney Real
Overlook Medical Center, Summit, New Jersey, USA	Robert Felberg, M.D., Igor Ugorec, M.D., Caroline Panter, Olivia Joy Eboras
St. Joseph's Hospital, Phoenix, Arizona, USA	Joseph Zabramski, M.D., Jean Lopez, Mary

	Harrigan
Hackensack University Medical Center, Hackensack, New Jersey, USA	Daniel Walzman, M.D., Jana Tancredi
St. Michael's Hospital, Toronto, Ontario, Canada	Julian Spears, M.D., Marlene Santos, Ph.D.
University of Calgary, Calgary, Alberta, Canada	John Wong, M.D., Teri Steward, Karla Ryckborst
University of Alberta, Edmonton, Alberta, Canada	Tim Darsaut, M.D., Brenda Poworoznik
Royal University Hospital, Saskatoon, Saskatchewan, Canada	Michael Kelly, M.D., Ruth Whelan
Oregon Health Sciences Center, Portland, Oregon, USA	Wayne Clark, M.D., Hormozd Bozorgchami, M.D., Darren Larsen, Monica Dolan
University Health Network, Toronto, Ontario, Canada	Michael Tymianski, M.D., Ph.D., Alex Kostynsky
Mount Sinai Medical Center, New York, New York, USA	Erol Gordon, M.D., Stephen Griffiths
Rush University Medical Center, Chicago, Illinois, USA	George Lopez, M.D., Josephine Volgi
North Shore Long Island Jewish Health System Lenox Hill Hospital, New York, New York, USA	John Boockvar, M.D., Michelle DeWitt

Supplemental Figure I: Diagram of the 2 parts, or dose-escalation and treatment parts of the study (top) and the 3 periods, or screening, treatment and follow-up, through which each patient was followed

Dose level/cohort:

PART 1
Dose-escalation part
Doses between 100 and 1200 mg subject to modification based on dose limiting toxicities and data monitoring committee recommendations



Maximum tolerated dose of EG-1962 established

Interim analysis of Part 1 for sample size estimation for Part 2

PART 2
Treatment part

